| Theme | The Current State of Management of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas | |
|---|---|---|
| Title | Pancreatic Ductal Adenocarcinoma (PDAC) Concomitant with IPMN | |
| Publish Date | 2014/12 | |
| Author | Yasuhisa Mori | Department of Surgery, Japanese Red Cross Fukuoka hospital |
| Author | Takao Ohtsuka | Department of Surgery 1, Kyushu University, Faculty of Medicine |
| Author | Norihiro Sato | Department of Surgery 1, School of Medicine, University of Occupational and Enviromental Health |
| Author | Koji Yamaguchi | Department of Advanced Treatment for Pancreatic Diseases, School of Medicine, University of Occupational and Enviromental Health |
| [ Summary ] | Intraductal papillary mucinous neoplasm (IPMN) is characterized by a papillary proliferation of the mucinous epithelium in the pancreatic duct. Since the International Consensus Guidelines were revised in 2012, appropriate management strategies for IPMN have been more clearly defined. The prevalence of distinct pancreatic ductal adenocarcinoma (PDAC) in patients with IPMNs, including synchronous and metachronous lesions, as well as other extrapancreatic malignant diseases, have been reported as 3-10 %. Therefore, clinicians should consider IPMN as a risk factor for distinct pancreatic ductal adenocarcinoma. Careful surveillance for IPMN might contribute to the early detection of PDAC, and thus to the improvement of its prognosis. | |